News
Sarepta Therapeutics suffered another major setback on Friday as Europe's drug regulator decided not to recommend the ...
Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.
Shares of drugmaker Sarepta Therapeutics continued to sink Tuesday after the company said it would comply with a Food and ...
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...
The FDA is set to request Sarepta Therapeutics to halt shipments of its gene therapy, Elevidys, after a third patient's death ...
The US Food and Drug Administration has approved a new system for nerve repair based on light-activated polymers rather than surgical stitches. The flexible polymer system was developed by the ...
Years later, Trump administration targets key figures in Russia investigation Word of the inquiry came as FBI and Justice Department leaders scramble to turn the page from mounting criticism from ...
The Justice Department appeared to acknowledge in an unusual statement this week the existence of investigations into former FBI Director James Comey and former CIA Director John Brennan.
Years later, key figures in Russia investigation face new scrutiny from Trump administration The Justice Department appeared to acknowledge in an unusual statement this week the existence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results